



## Disclaimer

This presentation has been prepared by Avantium N.V. (the "Company"). For the purposes of this notice, the presentation that follows (the "Presentation") shall mean and include the slides that follow, the oral presentation of the slides by the Company, the question-and answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation.

Some of the statements in this Presentation constitute forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements relate to future events or the Company's future financial performance. In some cases, forward looking statements can be identified by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially. In evaluating these statements, various risk factors should be taken into account. Risk factors may cause actual results to differ materially from any forward-looking statement. Although the Company believes that the expectations reflected in the forward looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of such statements. The Company is under no duty to update any of the forward-looking statements after the date of this Presentation or to conform such statements to actual results.

The information contained in this Presentation is for information purposes only. Avantium's reported financial results are prepared in accordance with International Financial Reporting Standards as adopted by the European Union. The information does not constitute or form part of, and should not be construed as, an offer to sell or issue, or a solicitation of any offer to buy or subscribe for any securities of the Company in any jurisdiction, and is not for publication or distribution in the US or to persons in the US (within the meaning of Regulation S under the US Securities Act of 1933 (the "Securities Act")), Canada, Japan, Australia or any other jurisdiction where such distribution or offer is unlawful. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of any securities in the United States. Subject to certain limited exceptions, neither this Presentation nor any copy of it may be taken, transmitted or distributed, directly or indirectly, into the US, its territories or possessions. The distribution of this Presentation in other jurisdictions may be restricted by law and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions.




# Opening and Agenda Items

1	Opening
2	Annual Report for the financial year 2024
3	Remuneration Report 2024 (advisory vote)
4	Adoption of the Annual Accounts 2024 (voting item)
5	Discharge from liability of members of the Management Board for the performance of their duties in financial year 2024 (voting item)
6	Discharge from liability of members of the Supervisory Board for the performance of their duties in financial year 2024 (voting item)
7	Re-appointment of Mr. T.B. van Aken (voting item)
8	Re-appointment of Mrs. M.G. Kleinsman (voting item)
9	Share consolidation and amendment of Articles of Association of the Company (voting item)
10	Designation of the Management Board to issue ordinary shares up to the statutory maximum of the authorised share capital and to limit or exclude pre-emptive rights in respect thereof, for a period of 18 months from the date of the AGM (voting item)
11	Re-appointment of PricewaterhouseCoopers Accountants N.V. as external auditor for the financial year 2025 (voting item)
12	Any other business (including Q&A)
13	Closing



Review 2024





## 2. Annual Report for the financial year 2024





## Highlights



Starting up the Flagship Plant



- Sales under the offtake agreements anticipated in H2 2025
- Creating the right conditions for future licensees



Groundbreaking polycotton textile waste technology



## A journey of almost two decades...

Laboratory FDCA Pilot Plant


















FID

Dec. 2021





Construction completed













Continuous

operation











## The FDCA Flagship Plant

- First-of-a-kind plant
- Enabling sales of FDCA & PEF at commercial scale
- Proving technology at 5kta scale
- Located in Delfzijl, The Netherlands
- Recruited operations team of 70 people
- Critical for a successful licensing strategy





## Starting up the FDCA Flagship Plant





FID





Construction phase





Start-up phase



Sugar Dehydration



Oxidation



FDCA Purification



Polymerization to PEF



Performance testing & regulatory validation



Sales of first FDCA and PEF to clients







# Releaf® | The next generation polymer, with superior performance benefits





10x better oxygen barrier










Note: Compared to PET



## Commitments from leading brands



16 Offtake

Offtake Agreements

2

Capacity Reservations Future Plants

1

Technology License Agreement

## Releaf® | Engaging brands and consumers





## The future: from pilot and flagship plant to license plants







Flagship Plant









2011




2025>




Annual General Meeting 14 May 2025

## Optimizing licensing strategy through the supply chain

Mitigating feedstock risk through 1<sup>st</sup> and 2<sup>nd</sup> gen strategy



Mitigating technology risk through FDCA Flagship Plant





## FDCA - feedstock agnostic, utilising Gen 1 and 2 feedstocks

1st Generation Feedstock



Glucose/fructose from starch

- FDCA Flagship Plant is using Gen 1 feedstock: starch an abundant co-product
- Regionally & commercially available
- Sugar surplus, no competition with food supply

2nd Generation Feedstock Innovations



Textile waste



Wood chips

- Feedstock availability crucial for effective global licensing strategy
- Avantium's Dawn Technology develops strategic diversifying feedstock options
- Recent breakthrough polycotton textile waste recycling



Annual General Meeting 14 May 2025

2<sup>nd</sup> generation feedstock: Dawn Technology enabling to use polycotton textile waste for feedstock

### The technology

 Avantium (together with the University of Amsterdam) developed a patented technology to break down the cotton in polycotton textile waste into glucose (2<sup>nd</sup> generation feedstock source for FDCA/PEF), while leaving the polyester intact for fiber-to-fiber recycling

#### Business case

 Scalable and cost competitive: successful Avantium Dawn pilot plant tests demonstrate high glucose yields from polycotton waste, proving the method's scalability and costeffectiveness

### Textile waste management

- Addressing global waste problem: with global textile production expected to reach 149 million tons by 2030 and a recycling rate of currently less than 1%, this technology can address a major textile waste problem
- Aligned with new regulations: Avantium's technology aligns with new regulations that make textile producers responsible for waste management

## Strategic importance

 Feedstock agnostic approach: reinforces the commercial potential of FDCA / PEF, supports Avantium's licensing strategy



**Publication in Nature Communications** 



Polyester residue of postconsumer polycotton waste textiles in the DAWN pilot plant



## Other business activities

#### Avantium R&D Solutions:

- Continued focus on four key areas of sustainable chemistry in 2024: green hydrogen, adsorption, sustainable chemical building blocks and chemical plastic recycling
- Revenues increased by 5% in 2024 to €14.3 million (FY 2023: €13.5 million)
- Avantium is actively exploring various strategic options to best position the R&D Solutions business to realize future growth

## Volta Technology:


- A multi-year agreement with SCG Chemicals was signed to enhance the existing partnership, using Volta Technology to pilot PLGA production
- Avantium is seeking external investment to spin out its Volta Technology as a stand-alone business

## Ray Technology<sup>™</sup>:

• After deciding to halt further investments in its Ray Technology™, Avantium continues to explore strategic options, including the potential sale of the technology (IP) and other related assets in 2025



## Non-financial highlights FY 2024



## Financial highlights FY 2024 (€ millions)





# Going concern

2024 financial statements are prepared on a going concern basis; however, a material uncertainty remains

Fundamental factors to Avantium's continuity		Measures to address material uncertainty
1.	The successful start-up of the FDCA Flagship Plant for Avantium RNP and achieving Commercial Operations Date	Detailed start-up plan in place
2.	The sale of technology licenses following achievement of the Commercial Operations Date of the FDCA Flagship Plant	Licensing strategy in place
3.	Refinancing or extension of Debt Financing Facilities before March 31, 2026	Continue to explore possibility of refinancing existing Debt Financing Facilities, and continue to work on meeting conditions for additional one-year debt extension to March 31, 2027
4.	Additional funding for the start-up and ramp-up of production from the FDCA Flagship Plant and for Avantium Renewable Polymers, as well as for all support activities and further development of Avantium's other technologies	The Company continues to explore various forms of additional financing including raising new equity, additional debt instruments, subsidies, as well as investigating strategic alternatives for its various business activities.







## 3. Remuneration Report 2024 (advisory vote)

- Our Remuneration Report describes the implementation of the Remuneration Policy for the Management Board and the Supervisory Board in 2024, which is set out on pages 84 to 105 of our Annual Report 2024
- Reference is made to the Remuneration Report 2024, published on the website of Avantium









## Preliminary voting results Remuneration Report 2024

For	Against	Abstained
23,699,097	123,100	842,376




## 4. Adoption of the Annual Accounts 2024 (voting item)

- Reference is made to the Annual Report 2024, published on the website of Avantium
- Mr Matze, partner
  PricewaterhouseCoopers Accountants
  N.V., presents the Auditor's Report





# **Pwc** Avantium N.V. | AGM presentation - Audit 2024



- Unqualified auditor's report
- Material uncertainty related to going concern
- Key Audit Matter Impairment assessment of the Avantium Renewable Polymer Cash Generating Unit
- All components in the group were in scope of our procedures






# Preliminary voting results Adoption of the Annual Accounts 2024

For	Against	Abstained
23,768,015	46,167	850,391



Discharge of Liabilities





5. Discharge from liability of members of the Management Board for the performance of their duties in financial year 2024 (voting item)



# Preliminary voting results Discharge Management Board 2024

For	Against	Abstained
23,602,014	54,653	1,007,906



6. Discharge from liability of members of the Supervisory Board for the performance of their duties in financial year 2024 (voting item)



# Preliminary voting results Discharge Supervisory Board 2024

For	Against	Abstained
23,602,114	54,553	1,007,906







## 7. Re-appointment Mr. T.B. van Aken (voting item)

Reference is made to the proposal in the explanatory notes to the agenda






#### Preliminary voting results Re-appointment Mr. T.B. van Aken

For	Against	Abstained
23,745,092	58,370	861,111



Composition of the Supervisory Board





#### 8. Re-appointment Mrs. M.G. Kleinsman (voting item)

Reference is made to the proposal in the explanatory notes to the agenda





#### Preliminary voting results Re-appointment Mrs. M.G. Kleinsman

For	Against	Abstained
23,746,345	47,322	870,906







# 9. Share consolidation and amendment of Articles of Association of the Company (voting item)

- The Company proposes to consolidate 10 shares to 1. This means that 10 (ten) ordinary shares will be consolidated into 1 (one) ordinary share.
- The share consolidation will take effect by an amendment of the nominal value per share in the authorised share capital of the Company.
- Because the authorised share capital has to be amended, it is proposed to set the new authorised share capital at the statutory maximum of five times the issued share capital.
- Reference is made to the proposal in the explanatory notes to the agenda







# Preliminary voting results Share consolidation and amendment of Articles of Association of the Company

For	Against	Abstained
23,734,503	644,132	285,938



Financing / mandate





10. Designation of the Management Board to issue ordinary shares up to the statutory maximum of the authorised share capital, and to limit or exclude preemptive rights in respect thereof, for a period of 18 months from the date of the AGM (voting item)







# Preliminary voting results Designation of the Management Board to issue ordinary shares

For	Against	Abstained
21,191,225	792,915	2,680,433



Other (corporate) affairs





11. Re-appointment of PricewaterhouseCoopers Accountants N.V. as external auditor for the financial year 2025 (voting item)







### Preliminary voting results Re-appointment of PwC Accountants N.V. as external auditor for 2025

For	Against	Abstained
22,314,328	1,512,929	837,316



Any other business





#### Preliminary voting results

No.	Agenda item	Outcome
3	Remuneration Report 2024	Adopted
4	Adoption of the Annual Accounts 2024	Adopted
5	Discharge from liability of members of the Management Board for the performance of their duties in financial year 2024	Adopted
6	Discharge from liability of members of the Supervisory Board for the performance of their duties in financial year 2024	Adopted
7	Re-appointment of Mr. T.B. van Aken	Adopted
8	Re-appointment of Mrs. M.G. Kleinsman	Adopted
9	Share consolidation and amendment of Articles of Association of the Company	Adopted
10	Designation of the Management Board to issue ordinary shares up to the statutory maximum of the authorised share capital and to limit or exclude pre-emptive rights in respect thereof, for a period of 18 months from the date of the AGM	Adopted
11	Re-appointment of PricewaterhouseCoopers Accountants N.V. as external auditor for the financial year 2025	Adopted

### 12. Any other business





